Back to Search Start Over

Adjuvant treatment of in-transit melanoma:Narrowing the knowledge gap left by clinical trials

Authors :
de Meza, Melissa M
Blokx, Willeke A M
Bonenkamp, Han J
Blank, Cristian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
Boers-Sonderen, Marye J
de Groot, Jan Willem B
Haanen, John B
Hospers, Geke A P
Kapiteijn, Ellen W
van Not, Olivier J
Piersma, Djura
van Rijn, Rozemarijn S
Stevense-Den Boer, Marion A
van der Veldt, Astrid A M
Vreugdenhil, Gerard
van den Eertwegh, Alfons J M
Suijkerbuijk, Karijn P M
Wouters, Michel W J M
de Meza, Melissa M
Blokx, Willeke A M
Bonenkamp, Han J
Blank, Cristian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
Boers-Sonderen, Marye J
de Groot, Jan Willem B
Haanen, John B
Hospers, Geke A P
Kapiteijn, Ellen W
van Not, Olivier J
Piersma, Djura
van Rijn, Rozemarijn S
Stevense-Den Boer, Marion A
van der Veldt, Astrid A M
Vreugdenhil, Gerard
van den Eertwegh, Alfons J M
Suijkerbuijk, Karijn P M
Wouters, Michel W J M
Source :
de Meza , M M , Blokx , W A M , Bonenkamp , H J , Blank , C U , Aarts , M J B , van den Berkmortel , F W P J , Boers-Sonderen , M J , de Groot , J W B , Haanen , J B , Hospers , G A P , Kapiteijn , E W , van Not , O J , Piersma , D , van Rijn , R S , Stevense-Den Boer , M A , van der Veldt , A A M , Vreugdenhil , G , van den Eertwegh , A J M , Suijkerbuijk , K P M & Wouters , M W J M 2023 , ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ' , International Journal of Cancer , vol. 153 , no. 2 , pp. 389-398 .
Publication Year :
2023

Abstract

Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyond clinical trials. In this study, we included stage III adjuvant-treated melanoma patients registered in the nationwide Dutch Melanoma Treatment Registry between July 2018 and December 2020. Patients were divided into three groups: nodal disease only, ITM only and ITM and nodal disease. Recurrence patterns, recurrence-free survival (RFS) and overall survival (OS) at 12-months were analyzed. In our study population of 1037 patients, 66.8% had nodal disease only, 16.7% had ITM only and 16.2% had ITM with nodal disease. RFS at 12-months was comparable in the nodal only and ITM only group (72.2% vs70.1%, P = .97) but lower in ITM and nodal disease patients (57.8%; P = .01, P < .01). Locoregional metastases occurred as first recurrence in 38.9% nodal disease only, 71.9% of ITM-only and 44.0% of ITM and nodal disease patients. Distant recurrences occurred in 42.3%, 18.8% and 36.0%, respectively (P = .02). 12-months OS was not significantly different for nodal disease only patients compared with ITM-only (94.4% vs 97.6%, P = .06) but was significantly higher for ITM-only compared with ITM and nodal disease patients (97.6% vs 91.0%, P < .01). In conclusion, we showed that in the adjuvant setting, RFS rates in ITM-only patients are similar to non-ITM, though better than in ITM and nodal disease patients. Adjuvant-treated ITM-only patients less often experience distant recurrences and have a superior OS compared with ITM and nodal disease patients.

Details

Database :
OAIster
Journal :
de Meza , M M , Blokx , W A M , Bonenkamp , H J , Blank , C U , Aarts , M J B , van den Berkmortel , F W P J , Boers-Sonderen , M J , de Groot , J W B , Haanen , J B , Hospers , G A P , Kapiteijn , E W , van Not , O J , Piersma , D , van Rijn , R S , Stevense-Den Boer , M A , van der Veldt , A A M , Vreugdenhil , G , van den Eertwegh , A J M , Suijkerbuijk , K P M & Wouters , M W J M 2023 , ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ' , International Journal of Cancer , vol. 153 , no. 2 , pp. 389-398 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1376785545
Document Type :
Electronic Resource

Tools

Authors Abstract Subjects Details